Hailshadow
- The UK’s Medicines & Healthcare products Regulatory Agency has issued a drug safety update regarding a “small risk” of Guillain-Barré syndrome associated with individuals who have received respiratory syncytial virus (RSV) vaccines made by GSK (NYSE:GSK) and Pfizer (NYSE:PFE).
- The former markets Arexvy; the latter, Abrysvo.
- “There is a small increase in the risk of Guillain-Barré syndrome following vaccination…in adults aged 60 years and older,” the alert states.
- It also says doctors should notify patients of the signs and symptoms of the condition, and if they occur to seek immediate medical attention.
- The U.S. labeling for both shots states that there is an increased risk of Guillain-Barré syndrome in the 42 days after vaccination based on post-marketing studies.
- Guillain-Barré syndrome is a rare autoimmune disorder where the body’s immune system mistakenly attacks the peripheral nerves.